A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder (Q38004948)

26 August 2017

0 references

A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

26 August 2017

0 references

1 reference

1

1 reference

26 August 2017

Leonardo F. Fontenelle

4

1 reference

26 August 2017

Nastassja Koen

2

1 reference

26 August 2017

Naomi Fineberg

3

1 reference

26 August 2017

Hisato Matsunaga

5

1 reference

26 August 2017

David Osser

6

1 reference

26 August 2017

H Blair Simpson

7

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Current Psychiatry Reports

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

211-219

1 reference

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Evidence based medicine: what it is and what it isn't

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Childhood-onset obsessive-compulsive disorder: a tic-related subtype of OCD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Gender differences in obsessive-compulsive disorder: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Use of selective serotonin reuptake inhibitors in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Postpartum onset obsessive-compulsive disorder: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Antidepressants and Body Weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

High-dose escitalopram for the treatment of obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Obsessive-compulsive disorder: a critical review of therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A review of antipsychotics in the treatment of obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A single-blinded case-control study of memantine in severe obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Effektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11920-012-0268-9

Venlafaxine in obsessive-compulsive disorder

21 January 2018

1 reference

12 December 2020

Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)

1 reference

12 December 2020

Response versus remission in obsessive-compulsive disorder

1 reference

12 December 2020

Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.

1 reference

12 December 2020

Clinical screening for obsessive-compulsive and related disorders.

1 reference

12 December 2020

The genetics of obsessive compulsive disorder: a review of the evidence

1 reference

12 December 2020

Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS).

1 reference

12 December 2020

Psychoeducation in anxiety disorders: Results of a survey of all psychiatric institutions in Germany, Austria and Switzerland

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

12 December 2020

Treatment of antidepressant nonresponders: augmentation or switch?

1 reference

12 December 2020

A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder

1 reference

12 December 2020

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

12 December 2020

The genetics of obsessive compulsive disorder and Gilles de la Tourette's syndrome

1 reference

12 December 2020

Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics

1 reference

12 December 2020

Treatment non-response in OCD: methodological issues and operational definitions

1 reference

12 December 2020

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases

1 reference

12 December 2020

Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial

1 reference

12 December 2020

Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study

1 reference

12 December 2020

Clomipramine and exposure for obsessive-compulsive rituals: i

1 reference

12 December 2020

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

1 reference

12 December 2020

Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders

1 reference

12 December 2020

Practice guideline for the treatment of patients with obsessive-compulsive disorder

1 reference

12 December 2020

Anxiety disorders following miscarriage

1 reference

12 December 2020

Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment

1 reference

12 December 2020

Female reproductive cycle and obsessive-compulsive disorder

1 reference

12 December 2020

Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder

1 reference

12 December 2020

Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study

1 reference

12 December 2020

Anxiety disorders in pregnant and postpartum women.

1 reference

12 December 2020

Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study

1 reference

12 December 2020

A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

1 reference

12 December 2020

Evidence-based pharmacotherapy of obsessive-compulsive disorder

1 reference

12 December 2020

10.1007/S11920-012-0268-9

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1025080938

0 references

1 reference